SEC Filings
State Street Holds 5.4% Of Collegium — It Has No Plan To Influence Control
The passive holding comes as ADHD-drug sales grow, generic competition cuts pain revenue and quarterly profit falls.
Collegium Pharmaceutical (COLL) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The passive holding comes as ADHD-drug sales grow, generic competition cuts pain revenue and quarterly profit falls.
Earnings
Jornay PM sales grew 24%, but operating expenses rose faster and Collegium kept its annual forecasts unchanged.
SEC Filings
The settlement also hands Collegium certain Nucynta-related patents, and Grünenthal has moved to dismiss its infringement suit.